PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34935423-10 2021 When tested in our in vitro model, we found evidence that aspirin can blunt cell signaling and endothelial dysfunction caused by bradykinin in these cells. Aspirin 58-65 kininogen 1 Homo sapiens 129-139 11356600-8 2001 However, after inhibition of cyclooxygenase and nitric oxide synthase with aspirin and NG-monomethyl-L-arginine, the forearm blood flow response to bradykinin (P = 0.003), but not to sodium nitroprusside (not significant), was significantly suppressed by miconazole. Aspirin 75-82 kininogen 1 Homo sapiens 148-158 10102747-3 1999 These potentiated effects of captopril and bradykinin were suppressed by Hoe-140, a kinin B2 receptor antagonist, or by concomitant addition of N(G)-nitro arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor, and aspirin, a cyclooxygenase inhibitor. Aspirin 226-233 kininogen 1 Homo sapiens 43-53 10400014-0 1999 Effect of acetylsalicylate on cardiac and muscular pain induced by intracoronary and intra-arterial infusion of bradykinin in humans. Aspirin 10-26 kininogen 1 Homo sapiens 112-122 10400014-1 1999 OBJECTIVES: This study assessed the algesic activity of bradykinin (BK) in humans and the effects of acetylsalicylate on muscular and cardiac BK-induced pain. Aspirin 101-117 kininogen 1 Homo sapiens 142-144 10400014-13 1999 The BK-induced pain is abolished or reduced by acetylsalicylate, thus suggesting that acetylsalicylate-sensitive mediators, such as prostaglandins, are involved in its pathogenesis. Aspirin 47-63 kininogen 1 Homo sapiens 4-6 10400014-13 1999 The BK-induced pain is abolished or reduced by acetylsalicylate, thus suggesting that acetylsalicylate-sensitive mediators, such as prostaglandins, are involved in its pathogenesis. Aspirin 86-102 kininogen 1 Homo sapiens 4-6 8339418-9 1993 Oral aspirin 75 mg/d for 14 days abolished bradykinin-induced PGI2 formation, whereas dermal aspirin 750 mg/d had no effect despite similar inhibition of TXA2 biosynthesis. Aspirin 5-12 kininogen 1 Homo sapiens 43-53 1891022-12 1991 The five- to sixfold increase in the prostacyclin metabolite induced by bradykinin was depressed by pretreatment for four days with 75 mg of immediate-release aspirin, but not by 75 mg of controlled-release aspirin. Aspirin 159-166 kininogen 1 Homo sapiens 72-82 34153179-9 2021 Acetyl salicylic acid (ASA), a nonspecific COX inhibitor, was able to mitigate a bradykinin-induced increase in PGE2 in our studies. Aspirin 0-21 kininogen 1 Homo sapiens 81-91 34153179-9 2021 Acetyl salicylic acid (ASA), a nonspecific COX inhibitor, was able to mitigate a bradykinin-induced increase in PGE2 in our studies. Aspirin 23-26 kininogen 1 Homo sapiens 81-91 34153179-10 2021 However, ASA was inflammatory above its therapeutic window, increasing the levels of PGE2 and IL-8 above those seen with bradykinin stimulation alone. Aspirin 9-12 kininogen 1 Homo sapiens 121-131 34153179-13 2021 An ASA-based formula (Biovanta) mitigated bradykinin-induced inflammation more strongly than ASA alone in organotypic human respiratory tissues. Aspirin 3-6 kininogen 1 Homo sapiens 42-52 3903519-0 1985 Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man. Aspirin 0-7 kininogen 1 Homo sapiens 41-51 2517685-3 1989 Bradykinin-induced relaxation was not inhibited by acetylsalicylic acid (10(-4) M), indomethacin (10(-6) M), and combined treatment with phentolamine (10(-6) M) and propranolol (10(-6) M). Aspirin 51-71 kininogen 1 Homo sapiens 0-10 2590611-2 1989 Effects of a single intravenous dose of aspirin (600 mg) on bradykinin-stimulated prostaglandin (PG) and on thromboxane (TX) biosynthesis were determined in nine healthy male volunteers. Aspirin 40-47 kininogen 1 Homo sapiens 60-70 2590611-5 1989 Aspirin inhibited bradykinin stimulated PG and platelet TX biosynthesis 0.5 h after the dose. Aspirin 0-7 kininogen 1 Homo sapiens 18-28 2825688-4 1987 This effect of bradykinin was unaffected by aspirin, and was accounted for by the amounts of NO released by the endothelial cells. Aspirin 44-51 kininogen 1 Homo sapiens 15-25 2889967-3 1987 The inhibitory action of both bradykinin and nitric oxide was abolished by haemoglobin, but not by aspirin, and was potentiated by superoxide dismutase to a similar degree. Aspirin 99-106 kininogen 1 Homo sapiens 30-40 3903519-7 1985 We report here that an oral dose of aspirin (600 mg) causes rapid and substantial inhibition of bradykinin-stimulated PGI2 production, but recovery occurs within 6 hours; this implies that endothelial PGI2 synthesis would be spared most of the time during dosing once daily with even this relatively large dose of aspirin. Aspirin 36-43 kininogen 1 Homo sapiens 96-106 6418250-5 1983 During the first 5 min after removal of the drugs from the incubation medium, bradykinin-stimulated release remains dose-dependently inhibited (P less than 0.001) in ASA-, but not in dipyrone-treated cultures. Aspirin 166-169 kininogen 1 Homo sapiens 78-88 6184749-4 1982 Bradykinin treatment of RPCT cells caused an accumulation of intracellular cAMP which was blocked by aspirin and was quantitatively similar to that observed with 10(-5) M PGE2. Aspirin 101-108 kininogen 1 Homo sapiens 0-10 4752265-0 1973 [Effect of aspirin on the response to the intradermal injection of bradykinin]. Aspirin 11-18 kininogen 1 Homo sapiens 67-77 485722-5 1979 When these procedures were after pretreatment with the analgesic agents, acetylsalicylic acid or dipyron a reduction in spike discharge was observed only with bradykinin after application of acetylsalicylic acid. Aspirin 73-93 kininogen 1 Homo sapiens 159-169 485722-5 1979 When these procedures were after pretreatment with the analgesic agents, acetylsalicylic acid or dipyron a reduction in spike discharge was observed only with bradykinin after application of acetylsalicylic acid. Aspirin 191-211 kininogen 1 Homo sapiens 159-169 6719-4 1976 The effects of bradykinin, A I and A II have been shown to be inhibited by aspirin but not by propranolol, metiamide, SC 19220 or a specific, competitive antagonist of A II. Aspirin 75-82 kininogen 1 Homo sapiens 15-25 4458701-0 1974 [Effects of acetylsalicylic acid on reflex cardiocirculatory and respiratory responses induced by injection of bradykinin into the femoral artery]. Aspirin 12-32 kininogen 1 Homo sapiens 111-121 27069632-0 2016 Comparative effects of immediate-release and extended-release aspirin on basal and bradykinin-stimulated excretion of thromboxane and prostacyclin metabolites. Aspirin 62-69 kininogen 1 Homo sapiens 83-93 5909493-0 1966 The effect of aspirin on pain and hand blood flow responses to intra-arterial injection of bradykinin in man. Aspirin 14-21 kininogen 1 Homo sapiens 91-101 28528204-6 2017 Moreover, aspirin differentially regulated the expression of a number of inflammation-related genes as it downregulated such pro-inflammatory genes as Nos2, Kng1, IL1beta, Ptgs2 or Ccr1, while it upregulated some anti-inflammatory genes such as IL10, Csf2, Cxcl1, Ccl5 or Tgfb1. Aspirin 10-17 kininogen 1 Homo sapiens 157-161 5784642-0 1969 Effect of acetylsalicylic acid and morphine on pressor responses produced by bradykinin. Aspirin 10-30 kininogen 1 Homo sapiens 77-87 27069632-12 2016 Both forms of aspirin decrease bradykinin-stimulated thromboxane and prostacyclin production, but some stimulated prostacyclin production remains during treatment with NHP-554C. Aspirin 14-21 kininogen 1 Homo sapiens 31-41 27069632-8 2016 Both doses of ASA and NHP significantly reduced excretion of both thromboxane and prostacyclin metabolites following intravenous bradykinin. Aspirin 14-17 kininogen 1 Homo sapiens 129-139 18789901-7 2008 Acetylcholine, bradykinin and sodium nitroprusside all caused dose-dependent vasodilatation in the presence and absence of aspirin and the "nitric oxide clamp" (P< or =0.005 for all). Aspirin 123-130 kininogen 1 Homo sapiens 15-25 20631409-12 2010 The thrombolytic actions of lipophilic ACE-Is (e.g., quinapril and perindopril) were prevented by pretreatment with either bradykinin B(2) receptor antagonists (e.g., icatibant) or with endothelial COX-2 inhibitors (e.g., rofecoxib, celecoxib and high dose aspirin). Aspirin 257-264 kininogen 1 Homo sapiens 123-133 18160362-5 2007 Theoretically, aspirin, which inhibits cyclooxygenase enzyme, may reduce bradykinin mediated prostaglandin synthesis and blunt the beneficial effects of ACE inhibitors, when used together. Aspirin 15-22 kininogen 1 Homo sapiens 73-83 18355801-0 2008 Aspirin inhibits human bradykinin B2 receptor ligand binding function. Aspirin 0-7 kininogen 1 Homo sapiens 23-33 18355801-2 2008 The effect of aspirin on bradykinin binding to cell-surface receptor and on signal transduction were studied in CHO-K1 cells, stably expressing the human B2 receptor. Aspirin 14-21 kininogen 1 Homo sapiens 25-35 18355801-5 2008 Aspirin reduces the apparent affinity of the receptor for [3H]-bradykinin by accelerating the dissociation rate of [3H]-bradykinin-receptor complexes. Aspirin 0-7 kininogen 1 Homo sapiens 63-73 18355801-5 2008 Aspirin reduces the apparent affinity of the receptor for [3H]-bradykinin by accelerating the dissociation rate of [3H]-bradykinin-receptor complexes. Aspirin 0-7 kininogen 1 Homo sapiens 120-130 18355801-6 2008 In addition, aspirin reduces the capacity of unlabeled bradykinin or the B2 receptor antagonist icatibant to destabilize pre-formed [3H]-bradykinin-receptor complexes. Aspirin 13-20 kininogen 1 Homo sapiens 55-65 18355801-6 2008 In addition, aspirin reduces the capacity of unlabeled bradykinin or the B2 receptor antagonist icatibant to destabilize pre-formed [3H]-bradykinin-receptor complexes. Aspirin 13-20 kininogen 1 Homo sapiens 137-147 12133028-1 2002 PURPOSE: To determine whether the prostacyclin-inhibiting properties of aspirin counteracts the bradykinin-induced prostacyclin-stimulating effects of angiotensin-converting enzyme (ACE) inhibitors, thereby attenuating the beneficial effects of ACE inhibitors in heart failure patients. Aspirin 72-79 kininogen 1 Homo sapiens 96-106 11849193-0 2002 Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor. Aspirin 10-17 kininogen 1 Homo sapiens 37-47